Alvotech and Teva Announce U.S. Approval of SIMLANDI (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira

24.02.2024 - Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SIMLANDI (adalimumab-ryvk) injection, as ...

Related Keywords

Ukraine ,Vietnam ,Republic Of ,United States ,Bangladesh ,Canada ,Yangtze River ,China General ,China ,Singapore ,Cambodia ,Thailand ,Taiwan ,Switzerland ,India ,Indonesia ,Malaysia ,Japan ,United Kingdom ,Australia ,South Korea ,Hong Kong ,Philippines ,New Zealand ,Pakistan ,Israel ,Robert Wessman ,Africa ,Eric Hughes ,Saval Latin America ,Alvotech Holdings ,Lotus Pharmaceuticals Co Ltd ,Abbvie Biotechnology Ltd ,Teva Pharmaceuticals ,Fuji Pharma Co Ltd Japan ,Teva Pharmaceutical Industries Ltd ,Kamada Ltd ,Yangtze River Pharmaceutical Group Co Ltd ,Oaktree Acquisition Corp ,Pharma Corporation Canada ,Chief Medical ,Abbvie Full Year ,Fourth Quarter ,Abbvie Biotechnology ,South America ,Teva Pharmaceutical Industries ,Advanz Pharma ,Cipla Med Pro ,Yangtze River Pharmaceutical ,Middle East ,Abdi Ibrahim ,Mega Labs ,Latin America ,Pharmaceutical Industries ,Idiopathic Arthritis ,Prescribing Information ,Private Securities Litigation Reform Act ,Oaktree Acquisition ,Note Regarding Forward Looking ,Teva Pharmaceutical Industries Aktie ,Lvotech Aktie ,